{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:10:58Z","timestamp":1778217058558,"version":"3.51.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Bone metastases occur in 65-75% of patients with metastatic breast cancer. They are often associated with skeletal-related events (SREs), leading to significant morbidity and decline in quality of life (QoL). Treatment with bone-modifying agents is crucial to decrease the risk of SREs and improve QoL. We used PubMed to review key clinical trials that studied the use of bisphosphonates (BPs) and denosumab for the treatment of osseous metastases in patients with metastatic breast cancer. We also reviewed agents that may have the potential to improve SREs. BPs \u2013 including clodronate, pamidronate, ibandronate, and zoledronic acid \u2013 as well as denosumab have shown efficacy and safety in the treatment of bone metastases secondary to breast cancer. Oral BPs are mainly used in Europe and other countries while zoledronic acid and denosumab are more commonly used in the United States. Zoledronic acid offers the convenience of a once-every-12-week dose. Denosumab may be superior. It is also associated with less renal toxicity and less acute-phase reactions. BPs and denosumab have shown good results; they are usually continued long-term as a palliative treatment. However, they are unlikely to revert osteolytic lesions. There is an unmet need for improvement of SREs. Bone-forming agents should be seriously considered for this purpose.<\/jats:p>","DOI":"10.3389\/fonc.2026.1823973","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:44:04Z","timestamp":1778215444000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of bone metastases in patients with breast cancer: review of bone-modifying therapy, emerging new agents, and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Gilbert","family":"Bader","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brianna","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Ohio State University Comprehensive Cancer Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley Pariser","family":"Davenport","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Gatti-Mays","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai CC","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerea","family":"Lopetegui-Lia","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dionisa","family":"Quiroga","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arya Mariam","family":"Roy","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Sardesai","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Stover","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.3.co;2-z","article-title":"Skeletal complications of Malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"B2","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v1.2026","year":"2026"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0093-7754(01)90260-x","article-title":"The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases","volume":"28","author":"Coleman","year":"2001","journal-title":"Semin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1172\/JCI3523","article-title":"TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development","volume":"103","author":"Yin","year":"1999","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125543","article-title":"Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness","volume":"5","author":"Hesse","year":"2019","journal-title":"JCI Insight"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23625","article-title":"Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases","volume":"123","author":"Bu","year":"2008","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11129","article-title":"Role of endothelin-1 in osteoblastic bone metastases","volume":"97","author":"Guise","year":"2003","journal-title":"Cancer"},{"key":"B12","article-title":"Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer","volume":"62","author":"Yi","year":"2002","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/bonekey.2015.122","article-title":"Mechanisms of osteolytic and osteoblastic skeletal lesions","volume":"4","author":"David Roodman","year":"2015","journal-title":"Bonekey Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"B15","article-title":"Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases","volume":"88","author":"Tubiana-Hulin","year":"2001","journal-title":"Bull Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.2165\/00044011-200626010-00006","article-title":"Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience","volume":"26","author":"McLachlan","year":"2006","journal-title":"Clin Drug Investig"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.2165\/00044011-200626060-00002","article-title":"Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial","volume":"26","author":"Pecherstorfer","year":"2006","journal-title":"Clin Drug Investig"},{"key":"B26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomized, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"crossref","first-page":"CD003474.pub2","DOI":"10.1002\/14651858.CD003474.pub2","article-title":"Bisphosphonates for breast cancer","volume-title":"Cochrane Database of Systematic Reviews","author":"Pavlakis","year":"2005"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2016.08.010","article-title":"Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study","volume":"81","author":"Chouinard","year":"2016","journal-title":"Regul Toxicol Pharmacol"},{"key":"B39","article-title":"A study of romosozumab in women with multiple myeloma and osteoporosis (NCT05775094)","volume-title":"ClinicalTrials.gov","year":"2025"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziaf144","article-title":"Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study","volume":"9","author":"Lopes","year":"2025","journal-title":"JBMR Plus"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000211","article-title":"Efficacy and safety of tanezumab in the treatment of pain from bone metastases","volume":"156","author":"Sopata","year":"2015","journal-title":"Pain"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4076","article-title":"LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption","volume":"22","author":"Luo","year":"2016","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1823973\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:44:17Z","timestamp":1778215457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1823973\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":42,"alternative-id":["10.3389\/fonc.2026.1823973"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1823973","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1823973"}}